Effect of apolipoprotein E (APOE) gene polymorphisms on the lipid profile of children being treated for acute lymphoblastic leukemia

期刊论文
出版模式：

开放获取
发表日期：

2024年3月20日

查看全文

Maria Ioannidou,
Chrysostomos Avgeros,
Elisavet Georgiou,
Aliki Papadimitriou-Tsantarliotou,
Dimitrios Dimitriadis,
Athanasios Tragiannidis,
Paraskevi Panagopoulou,
Evgenia Papakonstantinou,
Assimina Galli-Tsinopoulou,
Kali Makedou,
Emmanuel Hatzipantelis

摘要

Background

Medications used to treat acute lymphoblastic leukemia (ALL), such as l-asparaginase, can cause blood lipid disturbances. These can also be associated with polymorphisms of the lipoprotein lipase (LpL) and apolipoprotein E (APOE) genes.

Procedure

We aimed to investigate the association between lipid profile, certain LpL and APOE gene polymorphisms (rs268, rs328, rs1801177 and rs7412, rs429358 respectively) as well as the risk subgroup in 30 pediatric patients being treated for ALL, compared with 30 pediatric ALL survivors and 30 healthy controls.

Results

The only APOE gene polymorphism with significant allelic and genotypic heterogeneity was rs429358. Further analysis of this polymorphism showed that genotype (CC, CT, or TT) was significantly associated with (1) changes in the lipid profile at the end of consolidation (total cholesterol, LDL, apo-B100, and lipoprotein a) and during re-induction (total cholesterol and apo-B100), and (2) classification in the high risk-ALL subgroup (for CC genotype/C allele presence).

Conclusions

Lipid abnormalities in children being treated for ALL may be associated with the APOE genotype, which is also possibly associated with risk stratification. Further research is needed to confirm the potential prognostic value of these findings.